In breast cancer with PIK3CA mutations and urothelial cancer with FGFR3 translocations or mutations, Food and Drug Administration (FDA) approved phosphoinositide 3-kinases (PI3K) and fibroblast growth factor receptor (FGFR) inhibitors resp. Here, PIK3CA is linked to breast carcinoma.